Biotech breeding forces insurers to draw hard lines on equine risk

From a coverage standpoint, valuations are locked in early. “Purchase price, whether privately or at public auction, is the insurable value. When these horses get to be a yearling, a two-year-old, or older and start competing, that is when we will consider a higher value based on performance.” said Collier. However, he warned that genetically influenced pedigrees could artificially inflate prices – and insurers will be watching. “We’re going to have to be cognizant if prices get inflated because of these genetically enhanced pedigrees and be able to justify higher values.” 

Read More>>